Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes

NCT00255541 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00255541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00255541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2004
Completion date
December 31, 2006
Enrollment
580
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes